iTunes Google Play Stitcher TuneIn Amy Paller, MD & Adam Friedman, MD, FAAD To those who say you can only learn from your own experience, we call bluff. Dr. Amy…
Read More
For the millions of Atopic Dermatitis suffers, recent months have heralded a new age of both topical and system options to quench the flames of disease. How to approach this…
Read More
To those who say you can only learn from your own experience, we call bluff. Dr. Amy Paller, Chair of the Department of Dermatology, Director of the Skin Biology and…
Read More
By Allison Sit Babies may have a lower risk of eczema if their mothers take vitamin D during pregnancy, according to a new study in the British Journal of Dermatology.…
Read More
The June issue of the Journal of Drugs in Dermatology made several headlines with Healio recently. One article, “Rosacea More Common Than Expected Among Patients With Skin of Color,” was…
Read More
iTunes Google Play Stitcher TuneIn Shawn Kwatra, MD & Adam Friedman, MD, FAAD Pruritus is a pain for all those involved. Both a symptom and a disease simultaneously, one…
Read More
iTunes Google Play Stitcher TuneIn Shawn Kwatra, MD & Adam Friedman, MD, FAAD Being awarded a grant can seem insurmountable at times, with rejections and pink slips abound, but…
Read More
Pruritus is a pain for all those involved. Both a symptom and a disease simultaneously, one can feel like they are in the multiverse of madness. While we still have…
Read More
Being awarded a grant can seem insurmountable at times, with rejections and pink slips abound, but do not fret - you are not alone and we are itching to help. Tune…
Read More
By Allison Sit May marks the 20th anniversary of the Journal of Drugs in Dermatology. Launched in 2002 by dermatologist Perry Robins, MD, the JDD is now considered the fastest…
Read More
Healio published several articles recently about studies from the May issue of the Journal of Drugs in Dermatology. One article, “COVID-19 Precautions Linked with Delays in Skin Cancer Treatment,” was…
Read More
By Allison Sit The FDA has approved Olumiant (baricitinib) as a first-in-disease systemic treatment for adults with severe alopecia areata. Olumniant is a once-daily, oral JAK inhibitor. "People with alopecia…
Read More
